Search Result

Results for "

N-terminal domain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BCL6 (1) Androgen Receptor (7) Apolipoprotein (1) Apoptosis (7) Autophagy (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) CD47 (1) DNA/RNA Synthesis (1) Galectin (1) HIV (2) HSP (3) Influenza Virus (1) PROTACs (1) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROCK (1) SARS-CoV (2) Thrombin (1)
By Research Areas:	Cancer (15) Infection (6) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: Discoidin Domain Receptor Epigenetic Reader Domain JNK YTHDF VISTA WDR5 PIKfyve BCL6

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10152

INF7	Biochemical Assay Reagents	Infection
INF7 is a derivative of the N-terminal domain of the HA2 protein that can be used to enhance the endosomal escape of polyplexes or liposome-encapsulated proteins .

HY-123875A

Ralaniten triacetate EPI-506	Androgen Receptor	Cancer
Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active *androgen receptor (AR) N-terminal* domain (NTD)** inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7 .

HY-103076

EZ-482 1 Publications Verification	Apolipoprotein	Neurological Disease
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with K_ds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas .

HY-150102

EPI-7170	Androgen Receptor	Cancer
EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .

HY-P99777

Ontorpacept TTI-621	CD47	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-109070

Ralaniten EPI-002	Androgen Receptor	Cancer
Ralaniten (EPI-002) is a potent and orally active antagonist of the *androgen receptor-N-terminal* domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC₅₀** of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC) .

HY-16663

ITX3 2 Publications Verification	ROCK	Others
ITX3 is a specific and nontoxic inhibitor of TrioN (N-terminal GEF domain of the multidomain Trio protein) with an IC₅₀ value of 76 μM. ITX3 can be used for the research of agent .

HY-106723A

AMP-PCP disodium 1 Publications Verification	HSP	Cancer
AMP-PCP disodium is an ATP analogue and can bind to Hsp90 N-terminal domain with a K_d value of 3.8 μM. AMP-PCP disodium binding favors the formation of the active homodimer of Hsp90 .

HY-152078

Influenza virus-IN-6	Influenza Virus	Infection
Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PA_N) endonuclease inhibitor with an IC₅₀ of 0.20 μM .

HY-106723

AMP-PCP	HSP	Cancer
AMP-PCP is an ATP analogue and can bind to Hsp90 N-terminal domain with a K_d value of 3.8 μM. AMP-PCP binding favors the formation of the active homodimer of Hsp90 .

HY-139831

Galectin-8-IN-1	Galectin	Cancer
Galectin-8-IN-1 is a selective ligand for the *galectin-8 N-terminal* domain (galectin-8N)**, with a Kd of 48 μM and 15-fold selectivity over galectin-3 and even better selectivity over the other mammalian galectins.

HY-P2490

Acetyl-Hirudin (54-65) sulfated	Thrombin	Metabolic Disease
Acetyl-Hirudin (54-65) (sulfated) is a acetyl-fragment of Hirudin which binds directly to thrombin-rHCII(L444R) and disrupts interactions between the N-terminal acidic domain of rHCII and anion-binding exosite I of thrombin that serves to stabilize the complex .

HY-138779

ICCB-19 hydrochloride 1 Publications Verification	Autophagy RIP kinase Apoptosis	Inflammation/Immunology
ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins .

HY-138155

NSC15520	DNA/RNA Synthesis	Cancer
NSC15520 is a small molecular inhibitor of Replication Protein A (RPA). NSC15520 specifically recognizes the RPA N-terminal DNA binding domain (DBD), and blocks the interaction of RPA with p53 or RAD9. NSC15520 also inhibtis helix destabilization of a duplex DNA (dsDNA) oligonucleotide, involves in DNA replication, DNA repair, DNA recombination, and DNA damage response signaling .

HY-155478

Androgen receptor-IN-6	Androgen Receptor	Cancer
Androgen receptor-IN-6 (compound 16) is an orally available androgen receptor (Androgen Receptor) potent inhibitor (IC₅₀=0.12 μM in vitro), targeting the disordered N-terminal domain (NTD). Androgen receptor-IN-6 has good Caco2 cell membrane permeability and has an oral activity (F/%) of 16% in male CD-1 mice .

HY-114855

BT2 5 Publications Verification	Bcl-2 Family	Metabolic Disease
BT2 is a BCKDC kinase (BDK) inhibitor with an IC₅₀ of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC) . BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a K_i value of 59 μM .

HY-103078

I-XW-053	HIV	Infection
I-XW-053 is an inhibitor of HIV-1 capsid protein that can suppress the replication of HIV-189BZ167 with an IC₅₀ value of 164.2 μM. I-XW-053 exhibits antiviral activity and can block the interface between capsid protein (CA) N-terminal domains (NTD-NTD interface) with micromolar affinity .

HY-103078A

I-XW-053 sodium	HIV	Infection
I-XW-053 is an inhibitor of HIV-1 capsid protein that can suppress the replication of HIV-189BZ167 with an IC₅₀ value of 164.2 μM. I-XW-053 exhibits antiviral activity and can block the interface between capsid protein (CA) N-terminal domains (NTD-NTD interface) with micromolar affinity .

HY-W286614

RSK2-IN-4	Ribosomal S6 Kinase (RSK)	Inflammation/Immunology Cancer
RSK2-IN-4 (Compound 10) is a RSK2 inhibitor, with an inhibition rate of 13.73% on RSK2 activity at 10 μM. RSK2-IN-4 binds to the ATP-binding site of RSK2 in the NTKD (N-terminal kinase domain), with the electron-donating group at the 4-position of the phenyl ring being the key determinant for its inhibitory activity .

HY-P5320

TAT-BH4 (Bcl-xL)	Apoptosis	Others
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .

HY-P5320A

TAT-BH4 (Bcl-xL) (TFA)	Apoptosis	Others
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-172736

BMS-986458	PROTACs BCL6	Cancer
BMS-986458 is a highly selective and orally active BCL6 PROTAC degrader. BMS-986458 simultaneously co-opts cereblon (CRBN) and the BCL6 N-terminal BTB domain to catalyze proximity induced degradation of BCL6. BMS-986458 can be used for the study of B-cell Non-Hodgkin's lymphoma (Pink: Target protein ligand (HY-172740); Black: linker (HY-W267161); Blue: E3 ligase ligand (HY-W593794)) .

HY-149434

PROTAC AR-NTD degrader 1	Androgen Receptor Apoptosis	Cancer
PROTAC AR-NTD antagonist 1 (compound 18) is a small molecule protein-targeting chimera (PROTACs) targeting the Androgen Receptor AR-V7. PROTAC AR-NTD antagonist 1 antagonizes the N-terminal domain of AR (AR-NTD), degrades AR-V7 protein, and induces apoptosis in prostate cancer (PC) cells. The efficiencies of PROTAC AR-NTD antagonist 1 in degrading AR-V7 in VCaP cells were 62.2% (1 μM) and 71.1% (5 μM), respectively .

HY-164373

SC428	Androgen Receptor Apoptosis	Cancer
SC428 is an androgen receptor (AR) inhibitor that targets the N-terminal domain. SC428 potently decrease the transactivation of (AR)-V7, (AR)v567es, as well as full-length ( AR ) (AR-FL) and its LBD mutants, substantially. SC428 inhibits androgen-stimulated (AR)-FL nuclear translocation, chromatin binding, and (AR) -regulated gene transcription. SC428 inhibits the proliferation of tumor cells in vitro. SC428 inhibits tumor cell growth by inducing apoptosis in mice transplanted with 22RV1 .

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

HY-143418

SARS-CoV-2-IN-17	SARS-CoV	Infection
SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC₅₀ of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low K_D value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .

HY-143417

SARS-CoV-2-IN-16	SARS-CoV	Infection
SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC₅₀ of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low K_D value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library	731 compounds
A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases. MCE owns a unique collection of 731 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Histone Modification Research Compound Library

731 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 731 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.	Product Name	Target	Research Area

HY-P10152

INF7	Biochemical Assay Reagents	Infection
INF7 is a derivative of the N-terminal domain of the HA2 protein that can be used to enhance the endosomal escape of polyplexes or liposome-encapsulated proteins .

HY-P2490

Acetyl-Hirudin (54-65) sulfated	Thrombin	Metabolic Disease
Acetyl-Hirudin (54-65) (sulfated) is a acetyl-fragment of Hirudin which binds directly to thrombin-rHCII(L444R) and disrupts interactions between the N-terminal acidic domain of rHCII and anion-binding exosite I of thrombin that serves to stabilize the complex .

HY-P5320

TAT-BH4 (Bcl-xL)	Apoptosis	Others
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .

HY-P5320A

TAT-BH4 (Bcl-xL) (TFA)	Apoptosis	Others
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .

HY-P5340

Amyloid-Forming peptide GNNQQNY	Peptides	Others
Amyloid-Forming peptide GNNQQNY is a biological active peptide. (This is a heptapeptide from the N-terminal prion-determining domain of the yeast protein Sup35 that forms amyloid fibrils. The availability of its detailed atomic oligomeric structure makes it a good model for studying the early stage of aggregation. The GNNQQNY dimer forms three stable sheet structures. in-register parallel, off-register parallel, and anti-parallel. The in-register parallel dimer, which is close to the amyloid beta-sheet structure, has few interpeptide hydrogen bonds, making hydrophobic interactions more important and increasing the conformational entropy compared to the anti-parallel sheet.)

Cat. No.	Product Name	Target	Research Area

HY-P99777

Ontorpacept TTI-621	CD47	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

Conglobatin FW-04-806	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

Species:	Human (4)
Tag:	His (2) Tag Free (1) Avi (1) Fc (1)
Source:	HEK293 (1) Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72066

	ISCU Protein, Human (Sf9, His) 2310020H20Rik; HML; hnifU; Iron sulfur cluster assembly enzyme ISCU mitochondrial; Iron sulfur cluster scaffold homolog E. coli; ; Iron sulfur cluster scaffold homolog; Iron-sulfur cluster assembly enzyme ISCU; Iscu; IscU iron sulfur cluster scaffold homolog; ISCU_HUMAN; ISU2; MGC74517; mitochondrial; NIFU; NifU like N terminal domain containing; NifU like N terminal domain containing protein; NifU like protein; NifU-like N-terminal domain-containing protein; NifU-like protein; NIFUN; Nitrogen fixation cluster like; OTTHUMP00000238760; OTTHUMP00000238761; OTTHUMP00000238762; OTTHUMP00000238764; OTTHUMP00000238765	Human	Sf9 insect cells
	ISCU is an important mitochondrial scaffolding protein in the ISC assembly complex and forms the structural basis of [2Fe-2S] cluster assembly. ISCU relies on FXN to centrally receive persulfide during de novo synthesis initiated by the cysteine desulfurase complex (NFS1:LYRM4:NDUFAB1). ISCU Protein, Human (Sf9, His) is the recombinant human-derived ISCU protein, expressed by Sf9 insect cells , with N-6*His labeled tag.

HY-P701591

	LONRF2 Protein, Human LONRF2; LON peptidase N-terminal domain and RING finger protein 2; Neuroblastoma apoptosis-related protease; RING finger protein 192	Human	E. coli
	LONRF2 Protein, Human is the recombinant human-derived LONRF2 protein, expressed by E. coli , with tag free. The total length of LONRF2 Protein, Human is 753 a.a., .

HY-P701592

	LONRF2 Protein, Human (His) LONRF2; LON peptidase N-terminal domain and RING finger protein 2; Neuroblastoma apoptosis-related protease; RING finger protein 192	Human	E. coli
	LONRF2 Protein, Human (His) is the recombinant human-derived LONRF2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of LONRF2 Protein, Human (His) is 753 a.a., .

HY-P700705

	*DKK-1 N terminal* Domain Protein, Human (HEK293, Fc-Avi)** Dickkopf-related 1; Dickkopf-1; Dkk-1; Dkk1; hDkk-1; hDkk1; SK	Human	HEK293
	DKK-1 Proteinas are potent antagonists of canonical Wnt signaling, inhibiting LRP5/6-Wnt interactions and forming a ternary complex with KREMEN to promote LRP5/6 internalization.In addition to its proapoptotic function by antagonizing KREMEN1 independently of Wnt, DKK-1 also exhibits antiapoptotic activity.DKK-1 N terminal Domain Protein, Human (HEK293, Fc-Avi) is the recombinant human-derived DKK-1 N terminal Domain protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81230

	GSDMD Antibody DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human
	GSDMD Antibody is an unconjugated, approximately 53 kDa, rabbit-derived, anti-GSDMD polyclonal antibody. GSDMD Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, and predicted: mouse, rat background without labeling.

HY-P83706

	GSDMD Antibody (YA3443) DF 5L; DF5L; DFNA 5L; DFNA5L; FKSG 10; FKSG10; FLJ12150; Gasdermin D; Gasdermin domain containing 1; Gasdermin domain containing protein 1; Gasdermin domain-containing protein 1; Gasdermin-D; GasderminD; GSDMD_HUMAN; GSDMDC 1; GSDMDC1; Gasdermin-D, N-terminal; GSDMD-NT; hGSDMD-NTD; Gasdermin-D, C-terminal; GSDMD-CT; hGSDMD-CTD.	WB	Human
	GSDMD Antibody is an unconjugated, approximately 53 kDa, rabbit-derived, anti-GSDMD monoclonal antibody. GSDMD Antibody can be used for: WB expriments in human background without labeling.

HY-P81998

	Pirh2 Antibody (YA1743) RCHY1; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; RING finger and CHY zinc finger domain-containing protein 1; Androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger	WB	Human
	Pirh2 Antibody (YA1743) is a non-conjugated IgG antibody, targeting Pirh2, with a predicted molecular weight of 30 kDa (observed band size: 30 kDa). Pirh2 Antibody (YA1743) can be used for WB experiment in human background.